In Q3 2022, a precision oncology assay posted 38% quarter-over-quarter billable volume growth right after a Category I CPT code went live, and my market model — using September IQVIA claims signals — points to MAC coverage timing over a national GPO award or added lab capacity because IDN conversions lagged 1–2 buying cycles. Curious if your field teams saw the same cause-and-effect in comparable launches, or did contracting move the needle first?